Influenza is a major global public health threat as a result of its highly pathogenic variants, large 27 zoonotic reservoir, and pandemic potential. Metagenomic viral sequencing offers the potential of 28 a diagnostic test for influenza which also provides insights on transmission, evolution and drug 29 resistance, and simultaneously detects other viruses. We therefore set out to apply Oxford 30 Nanopore Technology to metagenomic sequencing of respiratory samples. We generated 31 influenza reads down to a limit of detection of 10 2 -10 3 genome copies/ml in pooled samples, 32 observing a strong relationship between the viral titre and the proportion of influenza reads (p = 33 4.7x10 -5 ). Applying our methods to clinical throat swabs, we generated influenza reads for 27/27 34 samples with high-to-mid viral titres (Cycle threshold (Ct) values <30) and 6/13 samples with low 35 viral titres (Ct values 30-40). No false positive reads were generated from 10 influenza-negative 36 samples. Thus Nanopore sequencing operated with 83% sensitivity (95% CI 67-93%) and 100% 37 specificity (95% CI 69-100%) compared to the current diagnostic standard. Coverage of full 38 length virus was dependent on sample composition, being negatively influenced by increased 39 host and bacterial reads. However, at high influenza titres, we were able to reconstruct >99% 40 complete sequence for all eight gene segments. We also detected Human Coronavirus and 41 generated a near complete Human Metapneumovirus genome from clinical samples. While 42 further optimisation is required to improve sensitivity, this approach shows promise for the 43 Nanopore platform to be used in the diagnosis and genetic analysis of influenza and other 44 respiratory viruses. 45 46
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Seasonal influenza causes an estimated 650,000 deaths globally each year, and H3N2 alone 53 kills 35,000 each year in the USA [1, 8] . Certain groups are particularly at risk, including older 54 adults, infants and young children, pregnant women, those with underlying lung disease, and 55 the immunocompromised [9] . The burden of disease disproportionately affects low/middle 56 income settings [10] . Influenza diagnostics and surveillance are fundamental to identify the 57 emergence of novel strains, to improve prediction of potential epidemics and pandemics [4, 11] , 58 and to inform vaccine strategy [12] . Diagnostic data facilitate real-time surveillance, can 59 underpin infection control interventions [13, 14] and inform the prescription of Neuraminidase 60
Inhibitors (NAI) [9] . 61 62 Currently, most clinical diagnostic tests for influenza depend on detecting viral antigen, or PCR 63 amplification of viral nucleic acid derived from respiratory samples [15] . These two approaches 64 offer trade-offs in benefits: antigen tests (including point-of-care tests (POCT)) are typically rapid 65 but low sensitivity [16-18], while PCR is more time-consuming but more sensitive [9] . 66
Irrespective of test used, most clinical diagnostic facilities report a non-quantitative (binary) 67 diagnostic result, and the data generated for influenza have limited capacity to inform insights 68 into epidemiological linkage, vaccine efficacy or anti-viral susceptibility. Given this, there is an 69 aspiration to generate new diagnostic tests that combine speed (incorporating potential for 70 POCT [19, 20] ), sensitivity, detection of co-infection [21, 22] , and generation of quantitative or 71 semi-quantitative data that can be used to identify drug resistance and reconstruct phylogeny to 72 inform surveillance, public health strategy, and vaccine design. 73
74
The application of Oxford Nanopore Technologies (ONT; https://nanoporetech.com/) to 75 generate full-length influenza sequences from clinical respiratory samples can address these 76 challenges. ONT offers a 'third-generation', portable, real-time approach to generating long-read 77 sequence data, with demonstrated success across a range of viruses [21,23-25]. To date, 78 Nanopore sequencing of influenza has been reported using high titre virus from an in vitro 79 culture system, producing full length genome sequences through direct RNA sequencing [26] or 80 targeted enrichment by either hybridisation of cDNA [27] or influenza-specific PCR amplification 81 [28] . 82
83
We therefore aimed to optimise a metagenomic protocol for detecting influenza viruses directly 84 from clinical samples using Nanopore sequencing. We determine its sensitivity compared to 85 existing diagnostic methods and its accuracy compared to short-read (Illumina) sequencing, 86 using clinical samples from hospital patients during an influenza season, and samples from a 87 laboratory controlled infection in ferrets. 88
Results

89
Method optimisation to increase proportion of viral reads derived from throat swabs 90
We first sequenced five influenza A positive and five influenza-negative throat swabs, each 91 spiked with Hazara virus control at 10 4 genome copies/ml. Using the SISPA approach [21] 92 followed by Nanopore sequencing, we produced metagenomic data dominated by reads that 93 were bacterial in origin, with extremely few viral reads detected. Passing the sample through a 94 0.4 µm filter prior to nucleic acid extraction increased the detection of viral reads by several 95 orders of magnitude ( Fig S1) . Filtration is relatively expensive, so we also assessed the 96 alternative approach of adding a rapid centrifugation step to pellet bacterial and human cells, 97 followed by nucleic acid extraction from the supernatant. We used a pooled set of influenza A 98 positive samples (concentration 10 6 genome copies/ml), to provide a large enough sample to 99 assess reproducibility, with the Hazara control spiked in at 10 4 genome copies/ml. Enrichment 100 for influenza and Hazara was similar for filtration vs centrifugation, based on reads mapping to 101 the viral genome ( Fig S2) . As centrifugation is simpler and cheaper, we selected this approach 102 for all further testing. 103 104
Method optimisation to reduce time for cDNA synthesis 105
Synthesis of tagged, randomly primed cDNA and its subsequent amplification via SISPA [21] 106 required lengthy reverse transcription and PCR steps (1h and 3h 45min) respectively. 107
Optimising these stages upgraded the reverse transcriptase from SuperScriptIII to 108 SuperScriptIV (ThermoFisher), reduced incubation time to 10min (processing time reduction of 109 50min) and reduced the PCR extension time within each cycle from 5min to 2min (1h 30min 110 processing time reduction). Comparing this final method with our original protocol, using 111 triplicate extractions from the pooled set of influenza A positive samples, demonstrated no 112 significant loss in performance in the more rapid protocol ( Fig S3) and we adopted this 113 approach as our routine protocol. 114 115
Consistent retrieval of Hazara virus by Nanopore sequencing 116
Starting with an influenza A positive sample pool (10 6 genome copies/ml), we made three 117 volumetric dilution series using three independent influenza-negative pools (Fig 1) . The total 118 quantity of cDNA after preparation for sequencing was consistently higher in all samples using 119 negative pool-3 as diluent (Fig 2A) , indicating the presence of a higher concentration of non-120 viral RNA within pool-3. This is likely due to host cell lysis or higher bacterial presence, and 121 demonstrates the variable nature of throat swab samples. 122
123
We consistently retrieved Hazara virus reads from all three dilution series by Nanopore 124 sequencing, independently of influenza virus titre in the sample ( Fig 2B) . Sequencing from 125 dilution series 1 and 2 gave a consistent proportion of total reads mapping to the Hazara 126 genome, across dilutions and between the first two pools with mean values per pool of 1.4x10 3 127 ±660 RPM (reads per million (of total reads) ± standard deviation) and 1.2x10 3 ±350 RPM 128 respectively. The pool-3 dilution series generated 260 ±340 RPM Hazara reads across samples, 129 and showed a decreasing trend associated with increased dilution factor, as increasingly more 130 non-viral RNA was introduced from this high-background pool. 131 132 Limit of influenza virus detection by Nanopore from pooled samples 133 Nanopore sequencing of the triplicate SISPA preparations of the influenza A positive pool 134 produced mean 5.3x10 4 ±3.6x10 4 RPM mapping to the influenza A genome ( Fig 2B) . Across the 135 dilution series, the proportion of influenza reads was strongly associated with influenza virus 136 titre (p-value = 4.7x10 -5 ), but was also influenced by which negative pool was used for dilution, 137 consistent with the pattern observed for the Hazara control. Sequencing the negative controls 138 (pools with no influenza virus spike) generated no reads mapping to influenza. At influenza virus 139 titres <10 3 copies/ml, influenza reads were inconsistently detected across the samples ( Fig 2B) , 140 suggesting the limit of detection is between 10 2 -10 3 influenza copies/ml. 141 142
Retrieval and reconstruction of complete influenza genomes from pooled/spiked samples 143
For the Hazara virus control (10 4 genome copies/ml spike), genome coverage was 81.4-99.4% 144 (at 1x depth) for pools 1 and 2. Coverage in the high-background pool 3 was more variable 145 (21.5-96.5%; Fig 3A) . Influenza A genome coverage at 10 6 copies/ml was ≥99.3% for each 146 segment in all samples ( Fig 3A) . At 10 4 genome copies/ml of influenza, mean 1x coverage per 147 segment was 90.3% for pools 1 and 2, but was substantially reduced in the high-background 148 pool 3 to 5.7% ( Fig 3A) . At influenza titres <10 4 copies/ ml, coverage was highly variable across 149 genome segments. However, when present at 10 3 copies/ml, 2/3 pools had sufficient data for 150 correct subtyping as H3N2 (Table 1) . 151 152
Influenza detection from individual clinical samples 153
Having demonstrated our ability to retrieve influenza sequences from pooled influenza-positive 154 material diluted with negative samples, we next applied our methods to individual anonymised 155 clinical samples, 40 testing influenza-positive and 10 influenza-negative in the clinical diagnostic 156 laboratory. Data yield varied between flow cells (range 2.5x10 6 -13.2x10 6 reads from up to 12 157 multiplexed samples). Within flow cells, barcode performance was inconsistent when using a 158 stringent, dual barcode, demultiplexing method [22] . From each clinical sample, the range of 159 total reads generated was 1.0x10 5 to 2.4x10 6 (median 3.8x10 5 ) (Table S1) . GeneXpert-negative samples (Table S1 ). Based on this small dataset, sensitivity is 83% and 167 specificity 100% (95% CI 67-93% and 69-100%, respectively). There was a strong correlation 168 between Ct value and both reads per sample classified as influenza (R-squared =0.604) and 169 number of influenza reads per million reads (R-squared =0.623) (Fig 4) . 170 171
Detection of Hazara virus internal control 172
Detection of the control virus (Hazara at 10 4 genome copies/ml) was highly variable, 173 demonstrating that levels of background non-target RNA are a major source of inter-sample 174 variation. Hazara reads per sample ranged from 0 to 13.5x10 3 (0-3.5x10 4 RPM) with a median 175 of 70 (160 RPM) and mean of 706 (1.7x10 3 RPM) (Table S1) to simplify and accelerate the protocol if it is to become viable as a near-to-patient test. High 230 error rates are a recognised concern in Nanopore sequence data, and cross-barcode 231 contamination can create challenges when low and high titre samples are batched together [22] . 232
To avoid these problems, we batched samples according to Ct value, and applied stringent 233 barcode demultiplexing criteria; however, this reduces the total data available for analysis [22] . 234
For future primary diagnostic use it would be preferable to sequence samples individually using sequence datasets provides an opportunity to investigate the relationship between within-host 275 polymorphisms and clinical outcomes. Long-read sequences confer the potential advantage of 276 identifying viral haplotypes and ascertaining the extent to which significant polymorphisms are 277 transmitted together or independently [25] . We have shown that the method is robust for the 278 identification of commonly circulating influenza strains in human populations, but further 279 investigation is required to ascertain the extent to which it performs reliably in other (avian, 280 animal) strains. 281
282
In summary, our methods show promise for generating influenza virus sequences directly from 283 respiratory samples. The 'pathogen agnostic' metagenomic sequencing approach offers an 284 opportunity for simultaneous testing for a wide range of potential pathogens, providing a faster 285 route to optimum treatment and contributing to antimicrobial stewardship. Longer term, this 286 approach has promise as a routine laboratory test, providing data to inform treatment, vaccine 287 design and deployment, infection control policies, and surveillance. 288
Methods
289
Study cohort and sample collection 290
We collected respiratory samples from the clinical microbiology laboratory at Oxford University 291 Hospitals NHS Foundation Trust, a large tertiary referral teaching hospital in the South East of 292
England. We worked with anonymised residual material from throat and nose swabs generated 293 as a result of routine clinical investigations, between January and May 2018. Samples were 294 collected using a sterile polyester swab inoculated into 1-3 ml of sterile viral transport medium 295 (VTM), using a standard approach as described on the CDC website [37] . Workflow is shown in 296 For methodological assessment, we focused on four categories of samples: 307
• Positive pool: we pooled 19 throat swab samples that had tested positive for influenza A 308 in the clinical diagnostic laboratory to provide a large enough sample to assess 309 reproducibility ( Fig 1B) ; 310
• Negative pools: we generated three pools of throat swab samples that had tested 
Quantification of viral RNA in samples 320
We quantified viral titres in Hazara virus stocks and pooled influenza A positive throat swabs by 321 qRT-PCR using previously described assays and standards [38, 39] . 322 323
Optimisation of methods 324
Prior to establishing the protocol detailed in full below, we assessed the impact of two possible 325 optimisation steps, as follows: 326 (i) Centrifugation vs filtration: We investigated two approaches to depleting human/bacterial 327 nucleic acid from our samples, filtration of the raw sample via a 0.4µm filter (Sartorius) before 328 further processing, versus a hard spin (16,000 xg for 2 min). cDNA libraries for this comparison 329 were produced as described previously [21] . 330 (ii) Reduced time cDNA synthesis: To assess the possibility of time-saving in the cDNA 331 synthesis steps, we compared performance of the previously described protocol [21] to a 332 modified version with two alterations, first using SuperScript IV (ThermoFisher) in place of 333 
Ferret study 401
We applied our sequencing approach to residual samples collected in a previous time-course 402 experiment undertaken in a controlled laboratory environment [30] . We tested ferret nasal saline 403 wash samples from three independent animals over an eight day time course, from three days 404 prior to first exposure with influenza H1N1pdm09 and at days 1, 2, 3 and 5 post-infection. 405
Sampling and plaque assays of viral titre were described previously [30] . 406 407
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